Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Administration, Oral
Aged
Androstenes
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Benzamides
Biopsy
Docetaxel
/ administration & dosage
Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Male
Nitriles
Phenylthiohydantoin
/ administration & dosage
Propensity Score
Prostate
/ diagnostic imaging
Prostatic Neoplasms, Castration-Resistant
/ diagnosis
Receptors, Androgen
/ metabolism
Retrospective Studies
Treatment Outcome
#PCSM
#ProstateCancer
ARAT
CRPC
intraductal carcinoma
prostate
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
14
12
2019
medline:
29
10
2020
entrez:
14
12
2019
Statut:
ppublish
Résumé
To evaluate the efficacy of docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with castration-resistant prostate cancer (CRPC) with intraductal carcinoma of the prostate (IDC-P) using a propensity score-matched analysis. We retrospectively identified 309 patients with CRPC from February 2007 to February 2016 at Nagoya University and its affiliated hospitals. All patients received initial androgen-deprivation therapy (ADT). After progression to CRPC, they received docetaxel or ARAT (abiraterone or enzalutamide) as first-line life-prolonging therapy. Docetaxel (70-75 mg/m Overall, 234 patients were analysed. Propensity score-matching identified 85 patients in each group. There were no significant differences in patient characteristics between the groups. The median OS in the docetaxel group was 38.2 vs 58.3 months in the ARAT group (P = 0.03). For patients with IDC-P, OS was significantly longer in the ARAT group than the docetaxel group (P = 0.01), and there was no significant difference in each group, as in patients without IDC-P (P = 0.67). A multivariate analysis showed that the presence of IDC-P, duration of primary ADT, visceral metastasis, and administration of ARAT as the first-line treatment for CRPC were independent prognostic factors for OS. Administration of ARAT as the first-line treatment for CRPC may prolong OS more than that of docetaxel, especially in patients with IDC-P.
Substances chimiques
Androstenes
0
Antineoplastic Agents
0
Benzamides
0
Nitriles
0
Receptors, Androgen
0
Docetaxel
15H5577CQD
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
abiraterone
G819A456D0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
702-708Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
Taylor RA, Fraser M, Rebello RJ et al. The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews. Urology 2019; 16: 281-90
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40: 244-52
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016; 70: 106-19
European Association Union. European Association of Urology Guidelines, 2018th edn. Arnhem, The Netherlands: European Association of Urology Guidelines Office, 2018
Kato M, Tsuzuki T, Kimura K et al. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol 2016; 29: 166-73
Kimura K, Tsuzuki T, Kato M et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680-7
Yamamoto A, Kato M, Matsui H et al. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. Int J Clin Oncol 2018; 23: 584-90
Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33
Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-60
Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-46
McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 1996; 20: 802-14
Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-79
Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-58
Chi K, Hotte SJ, Joshua AM et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 2015; 26: 2044-56
Bernard B, Muralidhar V, Chen YH et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 2017; 123: 1536-44
Lozano R, Castro E, Piulats JM et al. Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. J Clin Oncol 2019; 37(Suppl.); 264
Chen Z, Chen N, Shen P et al. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Prostate 2015; 75: 1247-54
Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019; 20: 686-700
Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019; 381: 121-31
Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13-24
Chi KN, Annala M, Sunderland K et al. A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). J Clin Oncol 2017; 35(Suppl.): 5002
Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
Frees S, Akamatsu S, Bidnur S et al. The impact of time to metastasis on overall survival in patients with prostate cancer. World J Urol 2018; 36: 1039-46